Puma Aims To File Nerlynx In Third-line HER2-positive Breast Cancer By July
Puma's CEO voiced confidence the biotech's lead asset Nerlynx will be approved in third-line HER2-positive metastatic breast cancer after its Phase III NALA study met co-primary endpoints.
You may also be interested in...
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.
Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.
Macrophage Pharma’s lead asset will advance to clinical trials next year, making a series B financing round necessary, the UK biotech’s CEO tells Scrip.